Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224607 · ClinicalTrials.gov registry record · NA
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
A NA study of Alzheimers Disease, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07224607: Recruiting NA study of Alzheimers Disease, sponsored by Cedars-Sinai Medical Center.
NCT07224607 is a NA study of Alzheimers Disease that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 45 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224607, a NA study of Alzheimers Disease, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to provide topical heating to elevate tissue temperature for temporary relief of muscle and joint pain, muscle spasm and stiffness associated with arthritis. It also increases blood circulation and relaxes muscle tissue. This device is being used "off-label," meaning it will be used in a way that is different than its cleared use. We want to learn whether this light treatment can improve executive function, and whether it changes certain inflammatory and neurodegeneration related signals in the blood. To do this, we will apply the photobiomodulation device to your forehead. We will also ask you questions and give you cognitive tests before and after light treatment. We will also collect blood samples before and after treatment.
Primary Outcome
Three validated NIH Toolbox tasks: 1. Dimensional Change Card Sort Task (measure of cognitive flexibility) 2. Flanker Inhibitory Control and Attention Test (a measure of inhibitory control and selective attention), 3. Visual Reasoning Test (non-verbal and visual reasoning)
Conditions Studied
Interventions
- DEVICE Photobiomodulation
Study Locations (1)
California
- CSMC - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-12-25 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT07224607 shows while recruiting
NCT07224607 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Photobiomodulation is the first listed.
NCT07224607 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07224607 about?
NCT07224607 is a clinical study titled "Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study". The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is clea...
What is the current status of trial NCT07224607?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-12-25. Estimated completion is 2026-10.
What conditions does trial NCT07224607 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT07224607?
The interventions under investigation include: Photobiomodulation (DEVICE).
Who is sponsoring clinical trial NCT07224607?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224607 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224607's enrollment target sits among peer trials
45 101st of 147 higher than 46 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
University of Central Florida Music Study
RECRUITING · NA
-
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment With Dementia Patients
RECRUITING · NA
-
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
RECRUITING · NA
-
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
RECRUITING · NA
-
Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI